Spectrum Pharmaceuticals traded at $1.03 this Monday July 31st. Looking back, over the last four weeks, Spectrum Pharmaceuticals lost 4.54 percent. Over the last 12 months, its price rose by 24.61 percent. Looking ahead, we forecast Spectrum Pharmaceuticals to be priced at 1.01 by the end of this quarter and at 0.95 in one year, according to Trading Economics global macro models projections and analysts expectations.
Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's product portfolio consists of in-development drug products for the treatment of cancer patients. Its pipeline products include ROLONTIS, Poziotinib and Anti-CD20-IFNa. ROLONTIS (eflapegrastim injection), is a long-acting granulocyte colony-stimulating factor (G-CSF) for chemotherapy-induced neutropenia. Poziotinib, is a pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR) family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations. Anti-CD20-IFNa, is an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for treating relapsed or refractory non-Hodgkin's lymphoma (NHL) patients.